| Literature DB >> 32158806 |
Nanda Kandamany1, Heather Tan1.
Abstract
The development of novel oral anticoagulant agents (NOACs) such as dabigatran, rivaroxaban, apixaban and edoxaban has given patients better treatment alternatives to aspirin, clopidogrel, heparin and warfarin, mainly for stroke prophylaxis in patients with non-valvular atrial fibrillation (NVAF), prophylaxis/treatment of venous thromboembolism (VTE) and also for the secondary prophylaxis of acute coronary syndromes. These agents are gaining in popularity due to their more stable pharmacokinetic profile, fewer drug interactions, as well as eliminating the need for routine monitoring. NOAC induced haematomas of the upper limb are rare and there is no real consensus on management. We present a case of a 70-year-old male on rivaroxaban who developed a delayed onset intramuscular forearm haematoma after a simple fall onto his left arm. Simple elevation of the limb was successful in leading to resolution of symptoms. As these agents increase in popularity, clinicians need to be more aware of potential risks of treatment and subsequent management. CrownEntities:
Keywords: Haematoma; NOAC; NOAC induced haematoma; Rivaroxaban; Upper limb
Year: 2018 PMID: 32158806 PMCID: PMC7061690 DOI: 10.1016/j.jpra.2017.08.008
Source DB: PubMed Journal: JPRAS Open ISSN: 2352-5878
Figure 1Forearm MRI in the axial plane, showing a focal haematoma (a) in the flexor digitorum superficialis muscle (b).
Figure 2Forearm MRI in the coronal plane showing the haematoma (a) within the flexor digitorum superficialis at the junction of the middle and distal thirds of the forearm.